Last reviewed · How we verify
Rivaroxaban (Xarelto)
Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation.
Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.
At a glance
| Generic name | Rivaroxaban (Xarelto) |
|---|---|
| Also known as | Anticoagulation |
| Sponsor | University of Michigan |
| Drug class | Direct Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rivaroxaban selectively inhibits Factor Xa, a serine protease essential for both the intrinsic and extrinsic pathways of the coagulation cascade. By blocking Factor Xa, the drug prevents the conversion of prothrombin to thrombin, thereby reducing thrombin-mediated fibrin clot formation. This anticoagulant effect is achieved with oral bioavailability and a predictable pharmacokinetic profile, eliminating the need for routine coagulation monitoring.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis (DVT) treatment and prevention
- Pulmonary embolism (PE) treatment and prevention
- Acute coronary syndrome
- Thromboprophylaxis after hip or knee replacement surgery
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
- Nausea
Key clinical trials
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (PHASE3)
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |